Effectiveness of Antibiotic Treatment for Reducing Binge Eating &

Status Completed

Clinical Trial Summary

This study will determine the effectiveness of the antibiotic erythromycin in enhancing gastrointestinal function and decreasing the frequency of binge eating in people with bulimia nervosa.

Clinical Trial Description

Bulimia nervosa (BN) is a serious eating disorder that is characterized by frequent uncontrolled eating binges. These binges are often followed by compensatory behavior, including the following: self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications to induce purging; fasting; or excessive exercise. If left untreated, BN can lead to many serious health issues: tooth decay; irregular menstruation; bowel damage; constipation; heart and kidney disease; intestinal damage; puffiness, especially in the face and fingers; increased hair growth on the face and body; and mineral imbalances in the body. Although there is significant existing knowledge about the characteristics and treatment of BN, more information is needed about gastrointestinal (GI) function and its effect on binge eating behavior. This study will determine the effectiveness of the antibiotic erythromycin in enhancing GI function and decreasing the frequency of binge eating in people with BN.

Participants in this 8-week, double-blind study will first undergo gastric emptying and GI hormone release testing for 1 day. Within 1 week of completing these pre-treatment tests, participants will be randomly assigned to receive either erythromycin or placebo for 6 weeks. Upon medication assignment, participants will meet with a psychiatrist to receive their assigned medication. Participants will receive medication at weekly study visits. Medication dosage will be increased if symptoms do not improve, or decreased if adverse medication side effects are reported. A final day of gastric emptying and GI hormone release testing, as well as routine blood tests, will take place in Week 7, after 6 weeks of medication treatment. Participants' weight will be measured at Weeks 1, 4, and 7. Participants will also receive an EKG 1 week after each upward dosage adjustment. Patients will be informed of their medication assignment at the Week 7 study visit, and will be referred to a non-study clinician for further treatment.

For information on related studies, please see NCT00308776 and NCT00307190. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00304187
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Completed
Phase	Phase 2
Start date	September 2004
Completion date	November 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05656859` - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed	`NCT04085861` - Mental Health in Dancers; an Intervention Study	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Terminated	`NCT04278755` - Binge Eating & Birth Control	Phase 2
Withdrawn	`NCT03050632` - Effects of Cognitive and Emotional Functioning on Treatment Outcomes	N/A
Completed	`NCT02567890` - Swedish Body Project for Prevention of Eating Disorders	N/A
Completed	`NCT02484794` - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application	N/A
Completed	`NCT02252822` - Improving Treatment Engagement for Adolescents With Bulimia Nervosa	N/A
Completed	`NCT02021344` - Mental Health First Aid for College Students	N/A
Completed	`NCT00601354` - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder	N/A
Completed	`NCT00418977` - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents	N/A
Completed	`NCT00733525` - Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa	N/A
Active, not recruiting	`NCT04779216` - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa	Phase 3
Completed	`NCT04433663` - Eating Disorders, Self Regulation and Mentalization	N/A
Recruiting	`NCT05509257` - Naltrexone Neuroimaging in Teens With Eating Disorders	Early Phase 1
Completed	`NCT04509531` - Building Resilience in Cyberbullying Victims	N/A
Recruiting	`NCT05730348` - Mealtime Anxiety in Eating Disorders
Enrolling by invitation	`NCT05814653` - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders	N/A
Completed	`NCT04506216` - Eating Disorders in Type 1 Insulin-dependent Diabetes Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms